Novitero
Computational drug design company focused on anticipating treatment-emergent resistance in cancer and designing small-molecule drugs adapted to bypass single, multiple and compound mutations. Uses molecular modeling, chemoinformatics and bioinformatics methods to predict mutational fingerprints, redesign existing scaffolds and develop patentable, outlicensed compounds. Founded and led by Dr. Itzchak Angel.
Industries
bioinformatics
biotechnology
health-care
oncology
pharmaceutical
Nr. of Employees
small (1-50)
Services
Prediction of resistance mutations and design of small-molecule compounds adapted to mutated targets using molecular modeling, dynamics, QSAR and de-novo design.
Prediction of resistance mutations and design of small-molecule compounds adapted to mutated targets using molecular modeling, dynamics, QSAR and de-novo design.
Expertise Areas
- Computational drug design
- Molecular modeling and simulation
- Structure-based and ligand-based lead optimization
- Prediction of drug-resistance mutations
Key Technologies
- Molecular dynamics simulation
- Free energy calculations
- Quantum mechanical / multiscale modeling
- Structure-based docking